These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38570906)

  • 1. Current issues in dose-finding designs: A response to the US Food and Drug Adminstration's Oncology Center of Excellence Project Optimus.
    Thall PF; Garrett-Mayer E; Wages NA; Halabi S; Cheung YK
    Clin Trials; 2024 Jun; 21(3):267-272. PubMed ID: 38570906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of adaptive trial designs for dose optimization.
    Zhang J; Chen X; Li B; Yan F
    Pharm Stat; 2023; 22(5):797-814. PubMed ID: 37156731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Realizing the promise of Project Optimus: Challenges and emerging opportunities for dose optimization in oncology drug development.
    Gao W; Liu J; Shtylla B; Venkatakrishnan K; Yin D; Shah M; Nicholas T; Cao Y
    CPT Pharmacometrics Syst Pharmacol; 2024 May; 13(5):691-709. PubMed ID: 37969061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A seamless phase II/III design with dose optimization for oncology drug development.
    Li Y; Zhang Y; Mi G; Lin J
    Stat Med; 2024 Aug; 43(18):3383-3402. PubMed ID: 38845095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statistical and practical considerations in planning and conduct of dose-optimization trials.
    Yuan Y; Zhou H; Liu S
    Clin Trials; 2024 Jun; 21(3):273-286. PubMed ID: 38243399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022.
    Araujo D; Greystoke A; Bates S; Bayle A; Calvo E; Castelo-Branco L; de Bono J; Drilon A; Garralda E; Ivy P; Kholmanskikh O; Melero I; Pentheroudakis G; Petrie J; Plummer R; Ponce S; Postel-Vinay S; Siu L; Spreafico A; Stathis A; Steeghs N; Yap C; Yap TA; Ratain M; Seymour L
    Ann Oncol; 2023 Jan; 34(1):48-60. PubMed ID: 36182023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DROID: dose-ranging approach to optimizing dose in oncology drug development.
    Guo B; Yuan Y
    Biometrics; 2023 Dec; 79(4):2907-2919. PubMed ID: 36807110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
    Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
    Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimus-Era Dose Finding for Rare Cancers.
    Murciano-Goroff YR; Devlin SM; Iasonos A; Drilon A
    Cancer Discov; 2024 Jun; 14(6):909-914. PubMed ID: 38826101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Embracing Project Optimus: Can we Leverage Evolutionary Theory to Optimize Dosing in Oncology?
    Qi T; Dunlap T; Cao Y
    Pharm Res; 2022 Dec; 39(12):3259-3265. PubMed ID: 36056271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innovations for phase I dose-finding designs in pediatric oncology clinical trials.
    Doussau A; Geoerger B; Jiménez I; Paoletti X
    Contemp Clin Trials; 2016 Mar; 47():217-27. PubMed ID: 26825023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-finding designs for trials of molecularly targeted agents and immunotherapies.
    Chiuzan C; Shtaynberger J; Manji GA; Duong JK; Schwartz GK; Ivanova A; Lee SM
    J Biopharm Stat; 2017; 27(3):477-494. PubMed ID: 28166468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seamless phase II/III design: a useful strategy to reduce the sample size for dose optimization.
    Jiang L; Yuan Y
    J Natl Cancer Inst; 2023 Sep; 115(9):1092-1098. PubMed ID: 37243720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Multi-Arm Two-Stage (MATS) design for proof-of-concept and dose optimization in early-phase oncology trials.
    Jiang Z; Mi G; Lin J; Lorenzato C; Ji Y
    Contemp Clin Trials; 2023 Sep; 132():107278. PubMed ID: 37419308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Applications of the partial-order continual reassessment method in the early development of treatment combinations.
    Wages NA; Dillon PM; Portell CA; Slingluff CL; Petroni GR
    Clin Trials; 2024 Jun; 21(3):331-339. PubMed ID: 38554038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology.
    Ji Y; Jin JY; Hyman DM; Kim G; Suri A
    Clin Transl Sci; 2018 Jul; 11(4):345-351. PubMed ID: 29392871
    [No Abstract]   [Full Text] [Related]  

  • 17. Early phase trial designs and endpoints for targeted therapies in rare genotype subsets.
    Mandrekar SJ
    Am Soc Clin Oncol Educ Book; 2014; ():e107-10. PubMed ID: 24857087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose optimization for cancer treatments with considerations for late-onset toxicities.
    Biard L; Andrillon A; Silva RB; Lee SM
    Clin Trials; 2024 Jun; 21(3):322-330. PubMed ID: 38591582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Competing designs for drug combination in phase I dose-finding clinical trials.
    Riviere MK; Dubois F; Zohar S
    Stat Med; 2015 Jan; 34(1):1-12. PubMed ID: 24464821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents.
    Wages NA; Tait C
    J Biopharm Stat; 2015; 25(5):903-20. PubMed ID: 24904956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.